Charles River Laboratories Intl. Inc (NYSE:CRL)
March 21st, 2019
With markets going up Charles River Laboratories Intl. Inc rose $1.61 Thursday, a 1.11% increase, closing at $146.73. Furthermore it hit a new 52 week high of $147.72.
Forecasts from 12 analysts points to the possibility that Charles River Laboratories Intl. Inc could rise somewhat (0.07%), while Finbox has calculated (with low uncertainty) a fair value price of $157.94.
The market sectors were mixed Thursday with a majority of the sectors trending up. Information Technology saw the biggest increase of the day (2.47%), while Financials saw the biggest drop (-0.30%). Information Technology has seen the biggest year-to-date gain at 21.08%.
Information Technology saw the biggest turnaround from its 5-day performance of 4.06%, as it went up 2.47%. Financials saw a turn around from its 5-day performance of -1.51% trading down -0.30%.
- Information Technology went up with a 2.47% change.
- Real Estate went up with a 1.79% change.
- Consumer Discretionary went up with a 1.32% change.
- Consumer Staples went up with a 1.19% change.
- Utilities went up with a 1.05% change.
- Materials went up with a 1.04% change.
- Industrials went up with a 0.95% change.
- Communication Services went up with a 0.89% change.
- Energy went up with a 0.69% change.
- Healthcare went up with a 0.35% change.
- Financials went down with a -0.30% change.
Charles River Laboratories Intl. Inc Info
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.